137 related articles for article (PubMed ID: 10097747)
1. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
2. [A clinical evaluation of the protective effect of fosfomycin (FOM) against the cis-diamminedichloroplatinum (CDDP)-induced nephrotoxicity].
Saito M; Masaki T; Kato H; Numasaka K
Hinyokika Kiyo; 1988 May; 34(5):782-9. PubMed ID: 3051938
[TBL] [Abstract][Full Text] [Related]
3. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
4. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
Yogi S; Ikeuchi T; Kai Y
Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
7. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial.
Benoehr P; Krueth P; Bokemeyer C; Grenz A; Osswald H; Hartmann JT
J Am Soc Nephrol; 2005 Feb; 16(2):452-8. PubMed ID: 15590762
[TBL] [Abstract][Full Text] [Related]
8. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
[TBL] [Abstract][Full Text] [Related]
9. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.
Hu YJ; Chen Y; Zhang YQ; Zhou MZ; Song XM; Zhang BZ; Luo L; Xu PM; Zhao YN; Zhao YB; Cheng G
Biol Trace Elem Res; 1997 Mar; 56(3):331-41. PubMed ID: 9197929
[TBL] [Abstract][Full Text] [Related]
10. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Nishimura G; Horiuchi C; Yoshida T; Kawakami M; Yabuki K; Taguchi T; Nagao J; Kondo N; Masuda Y; Matsuda H; Mikami Y; Tsukuda M
Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
[TBL] [Abstract][Full Text] [Related]
11. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract][Full Text] [Related]
12. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
13. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
14. [Clinical multivariate statistical analysis of nephrotoxicity induced by cisplatin].
Ding DC
Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):64-6. PubMed ID: 1396050
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
Unsal M; Erturk D
Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
[TBL] [Abstract][Full Text] [Related]
16. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
17. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
Schmidinger M; Budinsky AC; Wenzel C; Piribauer M; Brix R; Kautzky M; Oder W; Locker GJ; Zielinski CC; Steger GG
Wien Klin Wochenschr; 2000 Jul; 112(14):617-23. PubMed ID: 11008323
[TBL] [Abstract][Full Text] [Related]
18. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
19. [A study of CDDP in the treatment of patients with gastric and esophageal cancers, with special reference to the evaluation of renal functions before and after CDDP administration].
Sasaki E; Namatame K; Hirose C; Hamai N; Onomura Y; Miyata N; Kusumoto S; Makuuchi M; Iwai H; Asakawa K
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2713-7. PubMed ID: 3415269
[TBL] [Abstract][Full Text] [Related]
20. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
